Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ARNOLD L SILVA

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1497790646
CMS profile
158060
Location
MERIDIAN, ID

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$150,453.61

191 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ARNOLD L SILVA

NPI 1497790646 · CMS profile ID 158060

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

MERIDIAN, ID

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497790646?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ARNOLD L SILVA, NPI 1497790646, CMS profile ID 158060. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497790646?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ARNOLD L SILVA, NPI 1497790646, CMS profile ID 158060. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497790646?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ARNOLD L SILVA, NPI 1497790646, CMS profile ID 158060, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1497790646?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

191 matching records · $150,453.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 191 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–191 of 191.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CALLIDITAS THERAPEUTICS US INC. $25.8303/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141511209 CMS
Lilly USA, LLC $960.0003/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136051981 CMS
Travere Therapeutics, Inc. $300.0003/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149896452 CMS
GlaxoSmithKline, LLC. $242.2203/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116388108 CMS
GlaxoSmithKline, LLC. $1,793.2003/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116558869 CMS
Amgen Inc. $138.3303/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111708424 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $960.0003/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034321 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $40.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034259 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $40.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034261 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $50.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034265 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $50.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034267 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $50.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034269 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $185.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034293 CMS
Travere Therapeutics, Inc. $1,096.2702/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149896487 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $960.0002/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034319 CMS
Novartis Pharmaceuticals Corporation $16.5102/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087157685 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $40.4402/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034263 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $230.7802/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034295 CMS
Lilly USA, LLC $4,080.0002/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136000685 CMS
Lilly USA, LLC $720.0002/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136051979 CMS
Lilly USA, LLC $840.0002/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136064040 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $960.0002/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034317 CMS
Otsuka America Pharmaceutical, Inc. $24.6802/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118983032 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $146.8102/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034287 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $560.2402/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034311 CMS
AstraZeneca Pharmaceuticals LP $34.9502/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104317942 CMS
Lilly USA, LLC $2,400.0002/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136052931 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $231.1501/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034297 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $231.1501/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034299 CMS
Lilly USA, LLC $3,600.0001/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136051977 CMS
Novartis Pharmaceuticals Corporation $40.3201/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087157683 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $960.0001/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034315 CMS
Travere Therapeutics, Inc. $81.9101/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149896388 CMS
Travere Therapeutics, Inc. $2,418.0901/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149896507 CMS
GlaxoSmithKline, LLC. $3,900.0001/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115947133 CMS
GlaxoSmithKline, LLC. $57.0701/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116423029 CMS
GlaxoSmithKline, LLC. $3,900.0001/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116108065 CMS
GlaxoSmithKline, LLC. $1,300.0001/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116736878 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $960.0001/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118034313 CMS
GlaxoSmithKline, LLC. $10.0001/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115787943 CMS
GlaxoSmithKline, LLC. $393.8201/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116139982 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $85,364.52 166
PY2020 $31,709.50 65
PY2021 $102,003.18 134
PY2022 $80,734.07 116
PY2023 $71,307.98 126
PY2024 $150,453.61 191
PY2025 $103,928.07 174

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $347,489.14 47
PY2024 Principal investigator $215,310.81 34
PY2023 Principal investigator $169,341.45 40
PY2022 Principal investigator $353,709.27 147
PY2021 Principal investigator $355,162.16 389
PY2020 Principal investigator $427,309.73 102
PY2019 Recipient $1,528.89 9
PY2019 Principal investigator $585,853.40 295

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 12/17/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension PLLC-Nampa
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220659098
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 12/17/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension PLLC-Nampa
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220659100
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 12/17/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension PLLC-Nampa
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220659102
Principal investigator 1 ABBVIE INC. $19,581.00 12/04/2025 Non-covered Recipient Entity
CARE INSTITUTE LLC
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202528282
Principal investigator 1 Boehringer Ingelheim International GmbH $46.88 12/01/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension PLLC-Nampa
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220659096
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,124.00 11/24/2025 Non-covered Recipient Entity
ST LUKES CLINIC KIDNEY AND HYPERTENSION
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients No dispute reported 06/30/2026 1190308258
Principal investigator 1 Travere Therapeutics, Inc. $10,800.00 11/05/2025 Non-covered Recipient Entity
Care Cardio Renal Institute
DUPLEX study in FSGS No dispute reported 06/30/2026 1244186171
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $31,899.89 09/26/2025 Non-covered Recipient Entity
BOISE KIDNEY AND HYPERTENSION
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy No dispute reported 06/30/2026 1214124054
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,800.00 09/24/2025 Non-covered Recipient Entity
CARE INSTITUTE LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223285858
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 09/24/2025 Non-covered Recipient Entity
CARE INSTITUTE LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223285860
Principal investigator 1 Travere Therapeutics, Inc. $2,047.00 09/24/2025 Non-covered Recipient Entity
Care Cardio Renal Institute
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184148
Principal investigator 1 Travere Therapeutics, Inc. $250.00 09/09/2025 Non-covered Recipient Entity
Care Cardio Renal Institute
DUPLEX study in FSGS No dispute reported 06/30/2026 1244184143
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,500.00 09/02/2025 Non-covered Recipient Entity
CARE INSTITUTE LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223284739
Principal investigator 1 Travere Therapeutics, Inc. $602.00 09/01/2025 Non-covered Recipient Entity
Care Cardio Renal Institute
DUPLEX study in FSGS No dispute reported 06/30/2026 1244183919
Principal investigator 1 Travere Therapeutics, Inc. $500.00 09/01/2025 Non-covered Recipient Entity
Care Cardio Renal Institute
DUPLEX study in FSGS No dispute reported 06/30/2026 1244184152
Principal investigator 1 Travere Therapeutics, Inc. $1,250.00 08/18/2025 Non-covered Recipient Entity
Care Cardio Renal Institute
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184121
Principal investigator 1 Travere Therapeutics, Inc. $860.00 08/18/2025 Non-covered Recipient Entity
Care Cardio Renal Institute
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184125
Principal investigator 1 Travere Therapeutics, Inc. $500.00 08/18/2025 Non-covered Recipient Entity
Care Cardio Renal Institute
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184128
Principal investigator 1 Travere Therapeutics, Inc. $500.00 08/18/2025 Non-covered Recipient Entity
Care Cardio Renal Institute
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184133
Principal investigator 1 Travere Therapeutics, Inc. $250.00 08/18/2025 Non-covered Recipient Entity
Care Cardio Renal Institute
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184138
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,750.00 08/13/2025 Non-covered Recipient Entity
FRENOVA LLC
TAK-079-1006A STUDY OF MEZAGITAMAB IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY RECEIVING STABLE BACKGROUND THERAPY No dispute reported 06/30/2026 1223284125
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $152.55 08/13/2025 Non-covered Recipient Entity
FRENOVA LLC
TAK-079-1006A STUDY OF MEZAGITAMAB IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY RECEIVING STABLE BACKGROUND THERAPY No dispute reported 06/30/2026 1223284127
Principal investigator 1 Travere Therapeutics, Inc. $2,824.00 08/08/2025 Non-covered Recipient Entity
Care Cardio Renal Institute
DUPLEX study in FSGS No dispute reported 06/30/2026 1244184103
Principal investigator 1 Travere Therapeutics, Inc. $515.00 08/08/2025 Non-covered Recipient Entity
Care Cardio Renal Institute
DUPLEX study in FSGS No dispute reported 06/30/2026 1244184108
Principal investigator 1 Travere Therapeutics, Inc. $1,800.00 08/08/2025 Non-covered Recipient Entity
Care Cardio Renal Institute
DUPLEX study in FSGS No dispute reported 06/30/2026 1244184115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 08/01/2025 Non-covered Recipient Entity
Boise Kidney and Hypertension Institute - Boise - Frenova
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,200.00 08/01/2025 Non-covered Recipient Entity
Boise Kidney and Hypertension Institute - Boise - Frenova
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520362
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 07/25/2025 Non-covered Recipient Entity
Boise Kidney and Hypertension Institute - Boise - Frenova
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520356
Principal investigator 1 Travere Therapeutics, Inc. $6,515.60 07/07/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
Spartacus No dispute reported 06/30/2026 1244187161
Principal investigator 1 Alexion Pharmaceuticals, Inc. $32,759.23 03/27/2025 Non-covered Recipient Entity
FRENOVA RENAL RESEARCH
Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) No dispute reported 06/30/2026 1185540221
Principal investigator 1 Travere Therapeutics, Inc. $1,674.00 03/24/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184845
Principal investigator 1 Travere Therapeutics, Inc. $1,674.00 03/24/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184850
Principal investigator 1 Travere Therapeutics, Inc. $1,674.00 03/24/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184855
Principal investigator 1 Travere Therapeutics, Inc. $1,674.00 03/24/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184861
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,472.53 03/05/2025 Non-covered Recipient Entity
FRENOVA LLC
TAK-079-1006A STUDY OF MEZAGITAMAB IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY RECEIVING STABLE BACKGROUND THERAPY No dispute reported 06/30/2026 1223276053
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,027.00 02/26/2025 Non-covered Recipient Entity
FRENOVA RENAL RESEARCH
A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease No dispute reported 06/30/2026 1185540219
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $164,065.31 01/28/2025 Non-covered Recipient Entity
BOISE KIDNEY AND HYPERTENSION
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) No dispute reported 06/30/2026 1214124926
Principal investigator 1 Travere Therapeutics, Inc. $1,674.00 01/17/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184815
Principal investigator 1 Travere Therapeutics, Inc. $1,674.00 01/17/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184819
Principal investigator 1 Travere Therapeutics, Inc. $1,674.00 01/17/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184824
Principal investigator 1 Travere Therapeutics, Inc. $1,674.00 01/17/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184827
Principal investigator 1 Travere Therapeutics, Inc. $1,499.00 01/17/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184832
Principal investigator 1 Travere Therapeutics, Inc. $512.00 01/17/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184836
Principal investigator 1 Travere Therapeutics, Inc. $1,674.00 01/17/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244184841
Principal investigator 1 Travere Therapeutics, Inc. $1,674.00 01/17/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244185047
Principal investigator 1 Travere Therapeutics, Inc. $1,674.00 01/17/2025 Non-covered Recipient Entity
Boise Kidney And Hypertension
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244185050
Principal investigator 1 AstraZeneca Pharmaceuticals LP $905.85 01/08/2025 Non-covered Recipient Entity
ST LUKES CLINIC KIDNEY AND HYPERTENSION
TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal No dispute reported 06/30/2026 1185540223